Interleukin-18 binding proteins, their preparation and use

Details Interleukin-18 binding proteins, their preparation and use Interleukin-18 binding proteins, their preparation and use

2007-05-22

2007-05-22

Nickol, Gary (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S351000, C530S387300, C424S280100

Reexamination Certificate

active

09790338

ABSTRACT:
Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding them. DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided. Therapeutic uses of IL-18 binding proteins and further inhibitors of IL-18 are also provided according to the invention.

REFERENCES:
patent: 5776731 (1998-07-01), Parnet et al.
patent: 5932549 (1999-08-01), Allen et al.
patent: 5985863 (1999-11-01), Su et al.
patent: 6087116 (2000-07-01), Torigoe et al.
patent: 0850952 (1998-07-01), None
patent: 0864585 (1998-09-01), None
patent: 0974600 (2000-01-01), None
patent: WO 98/22137 (1998-05-01), None
patent: WO 98/24804 (1998-06-01), None
patent: WO 98/41232 (1998-09-01), None
patent: WO 99/06549 (1999-02-01), None
patent: WO 99/06553 (1999-02-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 00/12555 (2000-03-01), None
patent: WO 00/56771 (2000-09-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/19373 (2001-03-01), None
Adams, M.D. et al., EMBL Database Entry HSZZ16951, GenBank accession No. AA311795 (Apr. 18, 1997).
Adams, M.D. et al., EMBL Database Entry HZZ03012, GenBank accession No. g1950205 (Apr. 18, 1997).
Aizawa Y, Akita K, Taniai M, et al: Cloning and expression of interleukin-18 binding protein FEBS Lett. 445:338-342, 1999.
Akira S: The role of II-18 in innate immunity. Curr.Opin. Immunol. 12:59-63, 200.
Akita K, Ohtsuki T. Nukada, et al: Involvement of caspase-1 and caspase-3 in the production and processing of nature khuman interleukin 18 in monocytic THP.1 cells. J. Biol. Chem. 272:26595-26603, 1997.
Anderson, D.M., et al.,a homologue of theTNFreceptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997. 390(6656): p. 175-179.
Bollon, D..P., et al. (1980) J.Clin. Hematol. Oncol. 10:39-48.
Botstein, D., et al. (1982) Miami Wint. Symp. 19:265-274.
Broach, J.R., in “The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance”, Cold Spring Harbor Laboratory, Cold Sprong Harbor, NY, pp. 445-470 (1981).
Broach, J.R., (1982)Cell28:203-204.
Byrn R.A. et al, 1990,Nature(London) 344:667-670.
Car, B.D., V.M. Eng. B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock.J. Exp. Med. 179:1437-44 issn: 0022-1007.
Conti, B., J. W. Jahng, C. Tinti, J.H. Son, and T.H. Joh. 1997. Induction of interferon-gamma inducing factor in the adrenal cortex.J. Biol. Chem. 272:2035-2037.
Dao, T. Mehal WZ, Crispe IN: IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J. Immunol. 161:2217-2222, 1998.
Dao, T., K. Ohashi, T. Kayano M. Kurimoto, and H. Okamura. 1996. Interferon-gamma inducing factor, a novel cytokine, enhances Fas ligang-mediated cytotoxicity of murine T helper 1 cells. Cell-Immunol. 173:230-5 issn: 0008-8749.
Debets R, Timans JC, Churakowa T, et al: IL-18 Receptors, Their Role in Ligand Binding and Function: Anti-IL-IRAcPL Antibody, a Potent Antagonist of IL-18. J.Immunol. 165:4950-4956, 2000.
Dinarello CA, Novick D, Puren AJ, et al: Overview of interleukin-18: more than in interferon-gamma inducing factor. J. Leukoc. Biol. 63:658-664, 1998.
Dinarello CA:Il-18: A THI-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103:11-24, 1999.
Dinarello CA: Targeting interleukin 18 with interleukin 18 binding protein. Ann.Rheum.Dis 59 Suppl 1:117-120117-1202000.
EMBL Database Entry 0 00923, GenBank accession No. 0 00923 Jul. 26, 1993.
EMBL Database Entry 0 00919, GenBank accession No. 0 00919 Jan. 15, 1991.
Engelemann, H., D. Novick, and D. Wallach. 1990. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.J. Biol. Chem. 265:1531-1536.
Fantuzzi, G., et al.,IL-18 regulation of IFN-g production and cell proliferation as revealed in interleukin-lb converting enzyme-deficient mice. Blood, 1998. 91: p. 2118-2125.
Ghayur T, Banerjee S, Hugunin M, et al: Caspase-1 process IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619-623, 1997.
Gillepie MT, Horwood NJ: Interleukin-18: perspectives on the newest interleukin. Cytokine.Growth Factor. Rev.9:109-116, 1998.
Gracie JA, FOrsey RJ, Chan WL, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J.Clin.Invest. 104:1393-1401, 1999.
Gryezan, T., “The Molecular Biology of the Bacilli”, Academic Press, NY (1982), pp. 307-329).
Gu Y. Kuida K, Tsutsui H, et al: Activation of interferon-gamma inducing factor mediated by interleukin-I beta converting enzyme, Science 275:206-209, 1997.
Gutkind, J.S., et al.,A Novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphcytes buyt not in mormal momcytes. Molec. Cell. Biol., 1991. 11: p. 1500-1507.
Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billiau. 1990. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice.J. Exp. Med. 171: 1853-69 issn: 0022-1007.
Hillier, L. et al., EMBL Database Entry HSA 10059, GenBank accession No. AA010059 Nov. 29, 1996.
Hochholzer P, Lipford GB, Wagner H, et al: Role of Interleukin-18 (IL-18) during Lethal Shock: Decreased Lipopolysaccharide Sensitivity but Normal Superantigen Reaction in IL-18 Deficient Mice. Infect.Immun. 68:3502-3508, 2000.
Holmes S. Abrahamson JA, Al-Mahdi N, et al: Characterization of the in vitro and in vivo activiity of monoclonal antibodies to human IL-18. Hybridoma 19:363-367, 2000.
Horwood NJ, Udagawa N, Elliott J., et al: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin Invest. 101:595-603, 1998.
Hoshino K, Tsutsui H, Kawai T, et al: Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162:5041-5044, 1999.
Hyun KS, Rezinkow LL, Stuyt RJ, et al: Functional reconstitution and regulation of IL-18 activity by the IL-18RP chain [in Process Citation]. J. Immunol 166:148-154, 2001.
Hyun, KS, Eisenstein M, et al.: Structural Requirements of Six naturally Occurring Isoforms of the IL-18 Binding Protein to Inhibit IL-18. PNAS 97(3): 1190-1195.
John J.F., et al. (1986) Rev. Infect. Dis. 8:693-704).
Kendall, K.J. et al. (1987)J. Bacteriol. 169:4177-4183).
Kobayashi K, Nakata N, Kai M, et al: Decreased expression of cytokines that induce type 1 helper T cell/interferon-gamma response in genetically susceptible mice infected with Mycobacterium avium. Clin. Immunopathol. 85:112-116, 1997.
Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda and M. Kurimoto. 1997. INF-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Thl but not Th2 cells and exerts it effect independently of IL-12.J. Immunol. 158:1541-1550.
Kunikata T, Torigoe K, Ushio S, et al: Constitutive and induced IL-18 receptor expression by various periphal blood cell subsets as determined by anti-hiL-18R monoclonal antibody. Cell Immunol. 189:135-143, 1998.
Lebel-Binary S, Berger A, Zinzindohoue F, et al: Interleukin-18: biological properties and clinical implications [Review]. European Cytokine Network 11:15-25, 2000.
Leung BP, McInnes IB, Esfandiari E, et al: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J. Immunol. 164:6495-6502, 2000.
Maliszewski, C.R., T.A. Sato, T. Vanden Bos, S. Waugh, S.K. Dower, J. Slack, M.P. Beckmann, and K. H. Grabstein. 1990. Cytokine receptors and B cell functions. 1. Recombinant soluble receptors specifically inhibit IL-1 and IL-4 induced B cell activities in vitro.J. Immunol. 144:3028-3033.
Maniatis, T., in “Cell Biology: A Comprehensive Treatise. vol. 3: Gene Expression”. Academic Press. NY, pp. 563-608.
McInnes IB, Gracie Ja, Leung BP, et al

Affiliated with

Also associated with

Rating

Interleukin-18 binding proteins, their preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interleukin-18 binding proteins, their preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-18 binding proteins, their preparation and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3772621